These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum? Melamed E J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609 [TBL] [Abstract][Full Text] [Related]
25. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100 [TBL] [Abstract][Full Text] [Related]
26. Case report: successful use of rectally administered levodopa-carbidopa. Cooper SD; Ismail HA; Frank C Can Fam Physician; 2001 Jan; 47():112-3. PubMed ID: 11212422 [No Abstract] [Full Text] [Related]
27. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141 [TBL] [Abstract][Full Text] [Related]
28. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]
29. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
33. The effect of ventromedial tegmental lesions on the disposition and biosynthesis of dopamine and serotonin. Goldstein M; Battista AF; Anagnoste B; Ceasar PM; Fuxe K; Hökfelt T Adv Biochem Psychopharmacol; 1974; 10():45-53. PubMed ID: 4211049 [No Abstract] [Full Text] [Related]
34. The effect of dopamine and of apomorphine on dB-cAMP induced stimulation of synaptosomal tyrosine hydroxylase. Ebstein B; Roberge C; Tabachnick J; Goldstein M J Pharm Pharmacol; 1974 Dec; 26(12):975-7. PubMed ID: 4156865 [No Abstract] [Full Text] [Related]
36. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up]. Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540 [TBL] [Abstract][Full Text] [Related]
37. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537 [TBL] [Abstract][Full Text] [Related]
38. Acanthocytosis and spinocerebellar degeneration: a new association? Tsai CH; Chen RS; Chang HC; Lu CS; Liao KK Mov Disord; 1997 May; 12(3):456-9. PubMed ID: 9159749 [No Abstract] [Full Text] [Related]
39. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Brotchie JM Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705 [No Abstract] [Full Text] [Related]
40. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Encarnacion EV; Hauser RA Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]